The ability to detect rare mutations in a population of sequences is enabling for a wide range of molecular studies that relate shifts in genotype and phenotype to selective pressures. Although recent technologies have enabled the analysis of entire genomes for common variation, it is still very challenging to detect rare variants in a sample. This proposal aims to develop a new approach to detect rare genetic variants using next- generation sequencing. Our approach has implications for the development of diagnostic and theranostic tests, and the development of novel drugs to treat infectious diseases and cancer.

Public Health Relevance

There are over 200 diseases that are caused by mutations in the mitochondrial genome. Many of these mutations occur at a low frequency and are difficult to detect. By developing a powerful new method to detect rare variants, we aim to address an important unmet medical need.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HG006223-01A1
Application #
8252248
Study Section
Special Emphasis Panel (ZRG1-IMST-J (15))
Program Officer
Brooks, Lisa
Project Start
2012-05-15
Project End
2014-04-30
Budget Start
2012-05-15
Budget End
2014-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$233,691
Indirect Cost
Name
Prognosys Biosciences, Inc.
Department
Type
DUNS #
170943737
City
San Diego
State
CA
Country
United States
Zip Code
92121